Haleon gets target hike as UBS raises 'forever' sales target
- Haleon PLC (LSE:HLN, NYSE:HLN) has received a price target upgrade from UBS ahead of its third quarter update on 31 October as it becomes increasingly confident over its longer-term revenue opportunities. Foreign exchange movements will affect this year's adjusted earnings, which UBS has trimmed by 3%, but that aside the Swiss bank believes the GSK spin-iut has shown it can deliver 4-6% organic sales growth.
- 10/09/2024
|
Futura Medical in line for $5m milestone payment as Haleon's US Eroxon launch gets underway
- Futura Medical PLC (AIM:FUM, OTC:FAMDF) has secured a $5 million milestone payment following the US launch of its flagship product, Eroxon. The payment was triggered as Haleon, the company's distribution partner, began fulfilling online pre-orders and making fast-acting erectile dysfunction gel available in American retail stores.
- 10/07/2024
|
HLN or PODD: Which Is the Better Value Stock Right Now?
- Investors interested in stocks from the Medical - Products sector have probably already heard of Haleon PLC Sponsored ADR (HLN) and Insulet (PODD). But which of these two stocks is more attractive to value investors?
- 10/03/2024
|
Haleon's buy rating restated after Pfizer cuts down stake
- UBS has reiterated its buy rating on Haleon PLC (LSE:HLN, NYSE:HLN) shares after news that former parent company Pfizer Inc (NYSE:PFE, ETR:PFE) further pared down its stake in the FTSE 100-listed Sensodyne and Panadol maker. Haleon, which comprises the former consumer divisions of Pfizer and GSK PLC (LSE:GSK, NYSE:GSK), agreed on an off-market purchase of approximately £230 million worth of its own shares after Pfizer said t was cutting its stake by around £2.1 billion.
- 10/01/2024
|
Haleon buys back some shares as Pfizer sells down stake
- Haleon PLC (LSE:HLN, NYSE:HLN) said it has agreed to buy £230 million of its own shares from former co-parent Pfizer Inc (NYSE:PFE, ETR:PFE), which offloaded almost a $3.3 billion stake in the Sensodyne maker. The FTSE 100 consumer health group said made the purchase at a price of 308p per share.
- 10/01/2024
|
Pfizer offloads $3.3 bln stake in Sensodyne-maker Haleon
- Pfizer offloaded shares worth roughly $3.26 billion in Haleon at 380 pence apiece, cutting its stake to 15% in the world's largest standalone consumer healthcare firm, a bookrunner said on Tuesday.
- 10/01/2024
|
Pfizer to offload about 5.9% stake in UK's Haleon, says bookrunner
- Pfizer intends to offload about 540 million shares in the British consumer healthcare company Haleon , a bookrunner said on Monday.
- 09/30/2024
|
Sensodyne maker Haleon to raise stake in China JV
- British consumer healthcare company Haleon said on Friday it has agreed to raise its stake in its Chinese joint venture by 33% for 4.47 billion yuan ($637.35 million), taking its ownership to 88%.
- 09/27/2024
|
Haleon Selects PubMatic as Supply Optimisation Partner to Enable More Effective, Sustainable Media Buying
- The global healthcare brand gains increased transparency and control by getting closer to the sell-side of the ecosystem The global healthcare brand gains increased transparency and control by getting closer to the sell-side of the ecosystem
- 09/16/2024
|
Haleon lays out pricing for £1bn bond offering
- Haleon PLC (LSE:HLN, NYSE:HLN) has unveiled pricing for a near-£1 billion bond offering set to be carried out by its subsidiary this month. Some €750 million (£633 million) worth of Euro medium-term notes to mature in 2028 will be sold with a price of 2.875%, the FTSE 100-listed health firm announced Thursday.
- 09/12/2024
|
Haleon Announces the Launch of Eroxon®, The First and Only FDA Cleared OTC Gel for Erectile Dysfunction, Available for U.S. Preorder Without a Prescription
- Eroxon ® is Haleon's first offering in the sexual health space Clinical studies show Eroxon® is safe and effective in men with ED Eroxon® is available now for Amazon pre-order; available on shelves and online at most major retailers in October 2024 WARREN, N.J. , Sept. 3, 2024 /PRNewswire/ -- Eroxon® , the first-and-only FDA cleared gel available without a prescription for the treatment of erectile dysfunction (ED), is now available for pre-order in the United States through Amazon and will be available at most major retailers in October 2024.
- 09/03/2024
|
Haleon: Defensive Consumer Healthcare Stock As Safe Haven
- Haleon is a consumer healthcare company formed from a GSK and Pfizer merger, with a 50% share price increase since trading began. Financial results show strong cash flows, with a net profit of 754M GBP and EPS of 7.90 pence per share in the first half of the year. Investment thesis suggests writing put options due to the high EBITDA multiple, with the potential for decreasing net debt and increasing EBITDA in the future.
- 08/06/2024
|
Haleon, Reckitt, Wizz Air: Stocks lifting despite global sell-off
- While the FTSE 100 continues to suffer its worst session in recent times, dropping 2.5%, there are a handful of companies which have been able to buck the bearish trend. Out of London's blue chips, only Haleon and Reckitt have been able to lift into the green, up by 0.1% and 0.4% respectively.
- 08/05/2024
|
Haleon a rare riser on tough day as Deutsche Bank hilts resilience
- Haleon PLC (LSE:HLN, NYSE:HLN) interim results showed its resilience and dependability in very tough markets, suggests Deutsche Bank adding it deserves a higher rating. “The stock has been strong into results and the positive margin performance, along with some low season improvement in respiratory sell-out, is supporting the stock.
- 08/02/2024
|
Haleon plc (HLN) Q2 2024 Earnings Call Transcript
- Haleon plc (NYSE:HLN ) Q2 2024 Earnings Call August 1, 2024 4:00 AM ET Company Participants Sonya Ghobrial - Investor Relations Brian McNamara - Chief Executive Officer Tobias Hestler - Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS Bruno Monteyne - Bernstein Chris Pitcher - Redburn Atlantic David Hayes - Jefferies Rashad Kawan - Morgan Stanley Jeremy Fialko - HSBC Olivier Nicolai - Goldman Sachs Celine Pannuti - JPMorgan Iain Simpson - Barclays Operator Good morning, all. Thank you for joining us for the Haleon 2024 Half Year Results Q&A.
- 08/02/2024
|
Haleon ups profit guidance as power brands deliver
- Haleon upped its forecast for profit growth this year after a strong performance from its power brands Sensodyne, parodontax and Centrum in the first six months. The consumer brands giant now expects organic profits to rise by a ‘high single-digit percentage', compared to previous guidance of ‘ahead of' the revenue forecast of 4-6%.
- 08/01/2024
|
Futura Medical: Haleon ready launch Eroxon in the US before the year-end
- Futura Medical PLC (AIM:FUM, OTC:FAMDF) has received a boost from its blue-chip partner Haleon PLC (LSE:HLN, NYSE:HLN) on the timing of the US roll-out of Eroxon, Futura's fast-acting gel for erectile dysfunction. In its results statement earlier Thursday, the consumer products giant said Eroxon would be available Stateside before the year-end.
- 08/01/2024
|
Haleon sees high single-digit growth for annual organic operating profit
- Consumer healthcare firm Haleon on Thursday forecast high single-digit growth for its 2024 organic operating profit, after it posted a 4% rise in half-year pre-tax earnings amid strong demand for its oral care products and vitamins.
- 08/01/2024
|
HLN vs. LMAT: Which Stock Is the Better Value Option?
- Investors interested in Medical - Products stocks are likely familiar with Haleon PLC Sponsored ADR (HLN) and LeMaitre Vascular (LMAT). But which of these two stocks is more attractive to value investors?
- 07/17/2024
|
HLN vs. LMAT: Which Stock Should Value Investors Buy Now?
- Acadia Pharmaceuticals ACAD is a commercial-stage company focused on developing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders and rare diseases. ACAD's commercial portfolio comprises two marketed drugs — Nuplazid (pimavanserin) and Daybue (trofinetide).
- 07/16/2024
|
Haleon to quieten 'noise' with latest update, broker suggests
- Haleon PLC (LSE:HLN, NYSE:HLN) first half/second quarter results on 1 August should be the last of ‘noise and volatility' this year, suggests broker Jefferies. From here on, it should be a normalised base of sales says the US bank, which expects volumes and product mix to underline it can be a 4-6% organic growth business.
- 07/11/2024
|
Haleon to sell nicotine replacement therapy business outside US for $633 mln
- British consumer healthcare company Haleon said on Wednesday it would sell its nicotine replacement therapy business outside the United States to a unit of India's Dr. Reddy's for 500 million pounds ($632.55 million).
- 06/26/2024
|
Yellow Wood Partners Portfolio Company Suave Brands Company Completes ChapStick Acquisition
- BOSTON , June 3, 2024 /PRNewswire/ -- Yellow Wood Partners LLC ("Yellow Wood"), a Boston-based private equity firm known for investing in consumer brands and companies, is pleased to announce that its portfolio company, Suave Brands Company, has successfully completed the acquisition of the ChapStick brand from Haleon (LSE / NYSE: HLN). This transaction also results in Haleon becoming a shareholder in Suave Brands Company.
- 06/03/2024
|
GSK confirms exit of Haleon stake for £3.9 billion
- GSK PLC (LSE:GSK, NYSE:GSK) confirmed it has raised a total of £3.9 billion through the exit of its stake in Haleon PLC (LSE:HLN, NYSE:HLN), the healthcare firm which was spun out by the pharma giant back in 2022. On Friday, the Brentford-based firm revealed it raised £1.24 billion after it sold the final part of its stake in Haleon, offloading more than 385 million shares at 324p each.
- 05/17/2024
|
GSK raises $1.5 bln from offloading Haleon stake at a discount
- GSK has raised 1.25 billion pounds ($1.52 billion) from selling its entire remaining stake in consumer healthcare firm Haleon, the British drugmaker said on Friday.
- 05/17/2024
|
GSK intends to sell its remaining stake in Haleon
- British drugmaker GSK said on Thursday it plans to sell about 385 million shares, representing its entire shareholding, in spun-off consumer healthcare business Haleon.
- 05/16/2024
|
Haleon faces first short seller in Marshall Wallace
- Haleon PLC (LSE:HLN, NYSE:HLN), the FTSE 100 healthcare company, has seen £150 million of its shares shorted by Marshall Wace, the hedge fund. It represents the first time a short-seller of Haleon has made its position known since the company was spun out by pharma giant GSK two years ago.
- 05/13/2024
|
Haleon plc (HLN) Q1 2024 Earnings Call Transcript
- Haleon plc (NYSE:HLN ) Q1 2024 Earnings Conference Call May 1, 2024 4:00 AM ET Company Participants Sonya Ghobrial - Head, Investor Relations Tobias Hestler - Chief Financial Officer Conference Call Participants Rashad Kawan - Morgan Stanley Guillaume Delmas - UBS David Hayes - Jefferies Iain Simpson - Barclays Bruno Monteyne - Bernstein Victoria Petrova - Bank of America Celine Pannuti - JPMorgan Tom Sykes - Deutsche Bank Mikheil Omanadze - BNP Paribas Exane Chris Pitcher - Redburn Operator Ladies and gentlemen, welcome to the Haleon Q1 2024 Trading Update Conference Call. I am Davin, the chorus call operator.
- 05/02/2024
|
Haleon revenues fall in first quarter
- Advil and Sensodyne maker Haleon PLC (LSE:HLN, NYSE:HLN) kept its full-year outlook unchanged as it reported lower first-quarter revenue, though this was in line with expectations. Organic revenues were 3.0% higher than the same quarter last year, with sales volumes and product mix provided a negative contribution of 2%, held back by a weaker cold and flu season, offset by 5% price growth.
- 05/01/2024
|
Haleon's first-quarter revenue misses expectations
- Consumer healthcare company Haleon's first-quarter revenue missed market estimates on Wednesday, due to retailer destocking in the U.S., and a cool down in demand for cold and flu medication after a surge last year.
- 05/01/2024
|
Haleon eyes job cuts as UK manufacturing site 'no longer viable'
- News that Sensoyde toothpaste maker Haleon PLC (LSE:HLN, NYSE:HLN) could cut around 435 jobs as part of the shuttering of an oral products manufacturing site has lifted the shares 1.5%. The FTSE 100 group, which was spun out of GSK two years ago, is planning to close a site in Maidenhead in the next two years.
- 04/30/2024
|
Sensodyne-maker Haleon to shut UK manufacturing site, with more than 400 jobs hit
- Consumer healthcare company Haleon is planning to shut down its manufacturing site in Britain by 2026, which will impact 435 jobs, a spokesperson told Reuters on Tuesday.
- 04/30/2024
|
Haleon on course for sector leading earnings growth, analysts predict
- Haleon is due to report its first-quarter earnings on 1 May with UBS upping its organic sales growth forecast to 3.2% from 3.0% previously. Comparatives are tough in Respiratory Health and Pain Relief but these will be offset by expected continued strong momentum in Oral Health, said the bank.
- 04/09/2024
|
Haleon overhang can be gone in a year, suggests Barclays
- One of the biggest drags on the share price of consumer group Haleon might be gone by the end of the year suggests Barclays. According to the broker, and based on Pfizer's latest placing, it's possible it and GSK will have entirely sold down by the end of this year, leaving Haleon 100% free float, said the broker.
- 04/04/2024
|
Pfizer upsizes Haleon stake sale
- Haleon PLC (LSE:HLN, NYSE:HLN) said Pfizer Inc (NYSE:PFE, ETR:PFE) had sold a larger than expected amount of its shares overnight, scooping roughly £2.4 billion compared to the £2 billion expected, after the public offering was upsized. The FTSE 100-listed consumer goods company said the US and international offer had been priced at £3.08 per ordinary share and $7.85 per American Depositary Shares.
- 03/19/2024
|
Pfizer to sell down stake in Haleon
- Pfizer Inc (NYSE:PFE, ETR:PFE) has confirmed it will sell a large chunk of its stake in Haleon PLC (LSE:HLN, NYSE:HLN), raising over £2 billion (US$2.55bn). Haleon, a former consumer health joint venture between GSK and Pfizer that was spun out in 2022, aims to but £315 million of the shares, it said.
- 03/18/2024
|
Consumer healthcare giant Haleon says Pfizer to cut stake to 24%
- Consumer healthcare giant Haleon said on Monday that Pfizer will sell about 630 million of its shares in the company, reducing the US drugmaker's stake to about 24%.
- 03/18/2024
|
AHCO vs. HLN: Which Stock Should Value Investors Buy Now?
- Investors interested in Medical - Products stocks are likely familiar with AdaptHealth Corp. (AHCO) and Haleon PLC Sponsored ADR (HLN). But which of these two stocks offers value investors a better bang for their buck right now?
- 03/06/2024
|
Haleon building 'solid track record,' says Barclays
- Haleon steadied the ship last week for consumer staples suppliers after a results shock from Reckitt Benckiser, according to analysts at Barclays. Indeed, Haleon is building a solid track record of organic growth and making rapid progress on deleverage and capital return, added the broker.
- 03/04/2024
|
Haleon CEO: We expect to see volume growth in 2024
- Brian McNamara, CEO of Haleon, joins to discuss the firm's earnings. The consumer health company says it expects the operating environment to remain challenging, but is eyeing up to 6% organic revenue growth this year.
- 03/01/2024
|
Haleon plc (HLN) Q4 2023 Earnings Call Transcript
- Haleon plc (HLN) Q4 2023 Earnings Call Transcript
- 02/29/2024
|
Haleon Shares Rise 5%+ As Strong FY Results Drive Share Buyback Scheme
- FTSE 100-listed Haleon's share price leapt in Thursday trading, as strong sales growth and debt reduction in 2023 prompted it to launch a share repurchase programme.
- 02/29/2024
|
Haleon shares up 7% as it shrugs off mild cold and flu season and plans £500m buyback
- Haleon PLC (LSE:HLN, NYSE:HLN), the purveyor of medicine cabinet staples such as Panadol and Advil, joined Reckitt Benckiser PLC in suffering the effects of a mild cold and flu season. This, and slackening demand from China, were blamed for what is expected to be a slow first quarter of the new financial year.
- 02/29/2024
|
Consumer health giant Haleon sees higher revenue in 2024 on sustained demand
- Sensodyne toothpaste-maker Haleon said on Thursday it expected higher revenue in 2024, thanks to firm demand for its household products ranging from painkillers to multivitamins.
- 02/29/2024
|
British Airways, Ocado and Haleon to set next week's pace
- Scheduled company news is a little quieter after last week's rush of bank, mining and US tech updates, but there is still a decent stack of household names updating. Bunzl, the biggest company nobody has heard of, kicks off the week with British Airways owner IAG, GSK spin-off Haleon, Ocado and Pearson all due as well.
- 02/23/2024
|
Haleon garners mixed impressions from City analysts
- Analysts are divided over fast-moving consumer goods big cap Haleon PLC (LSE:HLN, NYSE:HLN)'s prospects prior to the FTSE 100-listed firm's annual results next month. According to Jefferies, Haleon is well-positioned to exceed both its organic sales and operating profit growth forecasts, placing it at the higher end of its full-year guidance.
- 01/30/2024
|
Haleon to recall batches of some adult cough syrups due to contamination
- Haleon is recalling some lots of its adult cough syrup Robitussin because of microbial contamination, the U.S. Food and Drug Administration (FDA) has said.
- 01/25/2024
|
Haleon sells ChapStick brand in bid to relieve debt pile
- Haleon PLC (LSE:HLN, NYSE:HLN), the healthcare company, confirmed the sale of its lip balm brand ChapStick for US$430 million, a company statement revealed. Suave Brands, a portfolio company of Yellow Wood Partners, will also provide Haleon with a minority stake worth around US$80 million as part of the deal.
- 01/25/2024
|
Haleon to sell ChapStick to Yellow Wood for about $510 million
- Britain's Haleon said it had agreed to sell lip balm brand ChapStick to a company owned by private equity firm Yellow Wood Partners for around $430 million in cash and a stake valued at around $80 million in the buyer.
- 01/25/2024
|
Haleon slides as forecasts trimmed ahead of full-year results
- Haleon PLC (LSE:HLN, NYSE:HLN) was the biggest faller on the FTSE 100 on Wednesday morning after JPMorgan fired off a warning shot ahead of the Sensodyne and Panadol maker's annual results next month. Having delivered strong volumes versus sector peers in the consumer staples sector over the past two years, the investment bank now expects the top line to disappoint as the tailwinds that boosted its over-the-counter divisions abate.
- 01/24/2024
|
GSK nets £978m from Haleon share sale
- GSK PLC (LSE:GSK, NYSE:GSK) said it completed the sale of 300 million shares in Haleon, the consumer health giant, netting £978 million, or $1.23 billion, in the process. The sum is around $200 million shy of the cash it is handing over to take over Aiolos Bio, the respiratory and inflammatory diseases specialists.
- 01/17/2024
|
GSK raises $1.24 bln from latest Haleon stake sale
- British drugmaker GSK said on Wednesday it had raised 978 million pounds ($1.24 billion) from a discounted stake sale in Haleon , cutting its shareholding to 4.2% in the world's largest standalone consumer healthcare firm.
- 01/17/2024
|
GSK to sell 3.2% stake in spin-off Haleon
- GSK will sell a 3.2% stake, or about 300 million shares, in its spun-off consumer healthcare business Haleon , the British drugmaker said on Tuesday.
- 01/16/2024
|
3 cheap 'stock'-ing stuffers Wall Street is bullish on
- Known for historically being the strongest month of the year for U.S. stocks, the Dow and S&P 500 both gained nearly 9% last month. The Nasdaq, almost 11%.
- 12/07/2023
|
Haleon's Long-Term Growth Prospects Look Healthy On Solid Macro Trends
- Haleon is a leading consumer healthcare company operating in the OTC medication, vitamins, minerals & supplements, and oral health segments. The company's strong brand and product moat make it less susceptible to recession impact, and its geographic diversification provides a stable financial base for growth. Despite challenges in the North American market and ongoing economic uncertainty, Haleon is trading at a significantly undervalued level with a potential upside of c.20%.
- 11/23/2023
|
Haleon: A Stable Pick
- Haleon sells health products internationally with stable operations and modest growth through a good performance in oral health products, and growth in Asia Pacific. The company's financials have remained solid with stable revenue increases and high EBIT margins. The stock seems to be priced for the good financials - I don't see significant upside or downside for the stock at the moment.
- 11/20/2023
|
The Investment Case For Haleon: Steady Shareholder Value Accumulation
- Haleon plc is a promising company in the personal care products sector, with a low beta and cheap valuation. The company operates globally and has leading brands in oral health, painkillers, and vitamins. Haleon's ownership structure is interconnected with Pfizer and GSK, but divestitures could increase competitive pressures.
- 11/20/2023
|
Haleon down as sales and earnings marginally undershoot - maintains full-year outlook
- Haleon PLC (LSE:HLN, NYSE:HLN)'s stock took a 2.6% hit in early trading, erasing roughly £800 million in market value, following the company's third-quarter revenue and profit report that fell short of market expectations. For the quarter ending September 30, Haleon reported a 5% organic increase in revenue, totalling £2.79 billion, slightly below the anticipated £2.83 billion.
- 11/02/2023
|
Advil maker Haleon's quarterly revenue rises on price hikes, strong demand
- Consumer healthcare company Haleon posted higher third-quarter revenue and stuck by its full-year forecasts on Thursday, helped by price hikes and resilient demand for its painkillers, cold and flu tablets, and oral health products.
- 11/02/2023
|
Haleon update expected to be reassuringly steady
- Haleon's third-quarter update won't be game-changing but will support a longer-term debt reduction thesis, suggests Citi. Organic sales growth should be 5.2% prices +4.7%), says the US bank, with a likely 3.9% increase forecast for the fourth quarter with flu volumes the drag.
- 10/27/2023
|
Sanofi to create its own Haleon, Kenvue as its stock price tumbles
- Sanofi (FRA: SNW), the giant healthcare company, is considering spinning off its consumer health business. In a statement, the management said it was hoping to create a separate company listed in France.
- 10/27/2023
|
7 Healthcare Stocks to invest in for a Healthy Future
- One of my favorite sectors will always be the healthcare sector. It is practically a basic need for all human beings and is always in constant development and growth.
- 10/20/2023
|
HLN vs. ABT: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Medical - Products sector have probably already heard of Haleon PLC Sponsored ADR (HLN) and Abbott (ABT). But which of these two stocks is more attractive to value investors?
- 10/06/2023
|
GSK banks almost £900m for Haleon stake sale
- GSK PLC (LSE:GSK, NYSE:GSK) has further reduced its stake in consumer health group Haleon PLC (LSE:HLN, NYSE:HLN), offloading 270 million shares for around £886 million. It is the second time in three months the drugs giant has lowered its holding in the maker of Sensodyne toothpaste and Panadol painkillers, raking in just under £1.9 billion in the process.
- 10/06/2023
|
GSK raises 886 mln pounds from Haleon stake sale
- British drugmaker GSK on Friday said it raised 885.6 million pounds ($1.08 billion) from a stake sale in its spun-off consumer healthcare business Haleon at 328 pence a piece.
- 10/06/2023
|
The Share Price Has The Flu, But Haleon Is As Healthy As An Ox
- Haleon's share price has slumped, but its performance is relatively better compared to its consumer staples peers and the recent listing Kenvue. HLN has delivered solid results with organic revenue growth, increased operating profits, and raised revenue forecasts for FY2023. The company is optimizing its portfolio, divesting the Lamisil brand, reducing debt, and generating strong cash flow. Power brands are driving performance.
- 09/07/2023
|
Haleon Upgrades Full-Year Sales Forecasts As Recent Trading Impresses
- The FTSE 100 healthcare firm said that revenues increased 10.6% in the first half, while pre-tax profit increased 11.1% year on year.
- 08/02/2023
|
Haleon upgrades guidance after strong first half
- British consumer healthcare giant, Haleon PLC (LSE:HLN, NYSE:HLN), has upgraded its full-year sales and earnings guidance for 2023, reflecting a solid first-half performance. The firm now expects organic revenue growth of 7-8%, up from its previous forecast of "towards the upper end of the 4-6% range.
- 08/02/2023
|
Haleon raises annual organic revenue growth forecast on steady demand
- Haleon on Wednesday raised its forecast for annual organic revenue growth as the consumer healthcare company is confident that demand for its oral and respiratory health products will stick despite a cost-of-living squeeze.
- 08/02/2023
|
BAE and Haleon earnings lead the way on Wednesday
- Defence contractor BAE Systems PLC (LSE:BA.) reports half-year numbers fresh from winning a host of contracts, including from the UK, Israel and Saudi Arabia.
- 08/01/2023
|
FTSE 100 forecast ahead of BP, LSE, HSBC, Haleon earnings
- The FTSE 100 index is hovering near the highest level in June as investors reflect on a slew of corporate earnings from some of the biggest constituents. The index was trading at £7,685 on Friday, a few points below this month's high of £7,707.
- 07/28/2023
|
Futura Medical announces chair succession after ‘landmark' Haleon tie-up
- Futura Medical PLC (AIM:FUM, OTC:FAMDF) has announced Jeff Needham as its new non-executive chair, succeeding from John Clarke who has stepped down. Clarke joined Futura in 2011 and, in a statement, the company described him as instrumental in driving the Company's strategy and success in securing commercial partnerships.
- 07/18/2023
|
Haleon an ‘excellent choice' for Futura's US ambitions, says broker
- Liberum has called Haleon PLC (LSE:HLN, NYSE:HLN) an “excellent choice” to take on commercialisation responsibilities in the US Futura Medical PLC (AIM:FUM, OTC:FAMDF)'s MED3000 topical, gel-based erectile dysfunction treatment. Under the deal, Haleon will be responsible for all investments and activities related to the launch and marketing of the product in the US, while Futura will provide ongoing technical support for over-the-counter product development and commercialisation opportunities.
- 07/17/2023
|
Futura Medical reaches deal with Haleon to commercialise ED treatment in US
- Futura Medical PLC (AIM:FUM, OTC:FAMDF) has entered into a licensing agreement with world-leading consumer health company Haleon PLC (LSE:HLN, NYSE:HLN) for the exclusive US commercialisation rights to Futura's topical, gel-based erectile dysfunction treatment MED3000 AIM-listed Futura, whose sexual health-focused proprietary drug technology DermaSys is in clinical development, will receive an upfront payment of US$4mln (£3mln), followed by royalty payments on all MED3000 sales by Haleaon, Haleon will be responsible for all investments and activities related to the launch and marketing of the product in the US, while Futura will provide ongoing technical support for over-the-counter product development and commercialisation opportunities. Erectile dysfunction is thought to affect at least one in five men globally.
- 07/17/2023
|
Haleon reportedly plans sweeping jobs cuts
- Haleon PLC (LSE:HLN, NYSE:HLN) intends to slash hundreds of jobs in the UK and potentially thousands worldwide, according to the Guardian. The company which makes Sensodyne toothpaste, Centrum vitamins and Panadol painkillers plans the widespread layoffs a year after being spun off from Britain's second-biggest drugmaker GSK.
- 07/14/2023
|
Haleon is considering offloading its brand of nicotine gum
- Haleon plc (LON: HLN) is in focus today following a report that it wants to divest its brand of nicotine gum, patches, and lozenges. Haleon wants to streamline its business Anonymous sources told Bloomberg this morning that the multinational has already picked an adviser to help with offloading its Nicotinell brand.
- 07/04/2023
|
Haleon considers sale of Nicotinell reports Bloomberg
- Haleon is exploring a potential sale of some smoking cessation products, including the Nicotinell brand of nicotine gum, patches and lozenges, according to Bloomberg. Citing people familiar with the matter, Bloomberg said the Weybridge, Surrey-based consumer healthcare products company is working with an adviser to identify potential suitors for the Nicotinell brand.
- 07/04/2023
|
GSK-spinoff Haleon exploring sale of Nicotine gum business - Bloomberg News
- Haleon , the world's biggest standalone consumer health business, is exploring the sale of its nicotine gum business as it aims to streamline its business, Bloomberg News reported on Monday, citing people familiar with the matter.
- 07/03/2023
|
HLN vs. SYK: Which Stock Should Value Investors Buy Now?
- Investors interested in stocks from the Medical - Products sector have probably already heard of Haleon PLC Sponsored ADR (HLN) and Stryker (SYK). But which of these two companies is the best option for those looking for undervalued stocks?
- 06/21/2023
|
Haleon: A Hidden Gem In The Consumer Health Market
- Haleon has a strong portfolio of leading brands and is well-positioned to benefit from ongoing market expansions. The company's latest earnings were strong, with double-digit growth in both the top and the bottom line. Despite the solid fundamentals and growth, its current valuation remains discounted compared to peers.
- 06/11/2023
|
HLN or SYK: Which Is the Better Value Stock Right Now?
- Investors with an interest in Medical - Products stocks have likely encountered both Haleon PLC Sponsored ADR (HLN) and Stryker (SYK). But which of these two stocks is more attractive to value investors?
- 06/05/2023
|
HLN or SYK: Which Is the Better Value Stock Right Now?
- Investors interested in stocks from the Medical - Products sector have probably already heard of Haleon PLC Sponsored ADR (HLN) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
- 05/18/2023
|
Haleon share price has stalled: is HLN a good buy now?
- Haleon (LON: HLN) share price has moved sideways in the past few days as GlaxoSmithKline (GSK) continued selling stake in the company. The shares also reacted mildly to the latest corporate earnings, which came earlier this month.
- 05/16/2023
|
Final Trades: Compass, Datadog, Transocean & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 05/10/2023
|
Unilever the top pick of the sector, above Reckitt and Haleon in analyst's last message
- Unilever PLC (LSE:ULVR), Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) and Haleon PLC (LSE:HLN, NYSE:HLN) all got their share price targets increased by broker Jefferies after a completed round of first quarter updates. Haleon, a year after being spun out from GSK, delivered the largest margin of beating the analyst consensus forecast, narrowly ahead of Reckitt but reservations remains and ‘hold' ratings were reiterated in an outgoing note on the sector after 16 years from analyst Martin Deboo.
- 05/09/2023
|
Haleon profits grow more slowly after mushrooming costs over past year
- Haleon PLC (LSE:HLN, NYSE:HLN) has grown profits more slowly in the first quarter of 2023 amid higher costs and unhelpful currency swings. The Volatrol and Centrum manufacturer remained confident of its organic sales guidance for the full year, towards the upper end of its 4-6% range, as revenue grew 9.9% in the first three months of the year.
- 05/03/2023
|
Haleon investors enjoy £700mln boost after trading update
- Just over £700mln was added to the value of Haleon PLC (LSE:HLN, NYSE:HLN), the consumer healthcare company that makes Advil and Sensodyne toothpaste, following an upbeat assessment of prospects. In a trading statement, it told the market it expects organic revenue growth in 2023 to approach the high end of its projected 4%-6% range, driven by robust demand and the replenishment of respiratory health products amid a severe cold and flu season.
- 04/20/2023
|
Haleon profit margin may disappoint, says Barclays
- Haleon PLC (LSE:HLN, NYSE:HLN) has "achievable" sales targets but it may struggle to meet the market's expected level of profit margins, according to Barclays. Analysts at the bank reiterated their "overweight" rating and 383p share price target.
- 04/19/2023
|
Haleon: difficult for shares to get significant re-rating says analyst
- Haleon PLC (LSE:HLN, NYSE:HLN) will find it difficult to get a significant re-rating for its shares, reckons Deutsche Bank. Following a meeting with the FTSE 100-listed consumer healthcare group's management, analyst Tom Sykes at the bank issued a note where he said the company has "a collection of quality brands but is still levered and is still very 'new' as an entity which brings with it some risk".
- 03/06/2023
|
Reckitt Benckiser, Flutter and Haleon under Thursday's broker spotlight
- City analysts were mostly in reaction mode on Thursday as the square-mile's CFA'd scribes continued to digest what has been a busy week of trading updates and results in London's mid-cap segment. Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) was tipped as a buy, at Royal Bank of Canada, so long as management execute on its plan to ‘normalise' in the coming months – that means no more write-offs and an altogether steadier few months of trading.
- 03/02/2023
|
Haleon falls to near 3m low as analysts blame 'technical factors'
- Haleon PLC (LSE:HLN, NYSE:HLN) shares fell to close to a three-month low after the consumer health group posted encouraging full-year numbers but analysts said “technical factors” would lead to downgrades for the 2023 forecasts. Including a maiden dividend, Barclays said the 2022 results overall were in line with City expectations, with organic sales growth of 9% “modestly better” and profit margins “slightly worse”.
- 03/02/2023
|
Haleon proposes first dividend as cash enables faster deleverage than expected
- Haleon PLC (LSE:HLN, NYSE:HLN) declared an inaugural dividend after its merger from GSK last year as price increases and efficiencies enabled increased profits and cash flow. The first dividend has been proposed at 2.4p per share, representing roughly 30% of adjusted earnings for the period since listing, with the board saying it intends to maintain the pay-out ratio around that level.
- 03/02/2023
|
Recent Stock Purchase/Sale February 2023
- There are two notable trades that are not buys this month as I decided to shuttle Haleon plc and GE HealthCare Technologies. Rarely does a spin-off these days equate to a solid real world standalone company.
- 02/27/2023
|
Haleon's reported strategic M&A dismissed as 'highly unlikely' and unwanted headache
- Haleon PLC's (LSE:HLN, NYSE:HLN) reported interest in large 'strategic scale' acquisitions, such as with Sanofi's consumer arm, have been panned by Barclays analysts as unlikely due to its need to reduce debt. The maker of Senodybe toothpaste, Panadol pain relief and other respiratory and vitamins, minerals and supplement (VMS) brands was said by Bloomberg yesterday to be looking at transactions for the medium to long term, with Sanofi Consumer Health a potential US$30bn merger candidate.
- 02/01/2023
|
Haleon: A Great Consumer Staples Add
- Haleon's consumer brands are strong, and its free cash flow margin is high at 16%. Net debt to EBITDA is expected to decrease to 3x in 2024.
- 01/31/2023
|
Haleon looks good on J&J read across, reckons Credit Suisse
- Haleon, the Glaxo personal care products spin-off, is an increasingly attractive option in the over-the-counter products space, according to Credit Suisse. Results this week from J&J Consumer Health's arm are directly comparable to Haleon, adds the broker, with a 55% overlap.
- 01/25/2023
|
Successful Data Analysis Could Be Game Changer For Haleon
- Haleon Plc is positioned as the world's largest company dedicated to the manufacture and marketing of personal care products. Haleon's power and positioning in the international market can be a bit better understood if we take into account its relationship with Pfizer and GSK plc.
- 01/20/2023
|
GSK's New Drugs and Pipeline Hold the Key to Growth in 2023
- GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion.
- 01/03/2023
|
Haleon upgraded by Barclays after Zantac litigation dismissed
- Barclays has upgraded its rating on Haleon PLC (LSE:HLN, NYSE:HLN) after Zantac-related litigation in the US was dismissed, meaning it will not proceed to trial unless there is a successfully appeal. For Haleon Zantac is "substantially derisked", leaving the shares "investible again for those without the appetite for pharma litigation risk", the bank said.
- 12/07/2022
|
Haleon Proves Its Mettle After GSK Spinoff
- On July 18, GSK PLC ( GSK , Financial) completed the long-awaited spinoff of its consumer health care business, Haleon PLC ( HLN , Financial). By separating the slow but steady consumer health business from the higher risk-reward pharmaceutical business, the spinoff was expected to drive GSK's stock valuation multiples higher, allowing it to fund more drug development and acquisitions.
- 12/06/2022
|
Haleon's Dilemma: To Wait Or Not To Wait
- Haleon plc is a new IPO that seems to have a bright future. Its conservative business model and significant moat make Haleon a long-term value play.
- 11/26/2022
|
GSK spinoff Haleon lifts guidance as revenue rises on higher sales and volumes
- By Michael Susin
- 11/10/2022
|
Haleon hikes organic revenue guidance after sustained price increases
- Haleon PLC (LSE:HLN, NYSE:HLN) upped its outlook for organic revenue growth and profits this year as the Sensodyne and Panadol maker benefited from increasing its prices to offset cost inflation. The FTSE 100-listed consumer health group, which was spun out of GSK in the summer, said it now expects organic revenue to grow 8.0-8.5% over the full year, with adjusted operating profit margin “slightly above” last year, at actual exchange rates.
- 11/10/2022
|
GSK's Q3 Earnings Beat, Ups 2022 Sales Outlook, Stock Up
- GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises the full-year sales guidance for all its segment
- 11/02/2022
|
Haleon third-quarter update is big date for Pfizer stock overhang
- Looming over Haleon PLC (LSE:HLN, NYSE:HLN) as it reports third-quarter numbers on Thursday 10 November are a couple of big issues. The date itself is important, and this is when an overhang from the combined 45% stake owned by former parents GSK PLC (LSE:GSK, NYSE:GSK) and Pfizer PLC could start to come into play.
- 11/02/2022
|
Haleon sales targets impress Barclays
- Haleon was a top FTSE 100 riser Tuesday after a bullish write-up by analysts at Barclays following a three-day road trip with management of the consumer goods and healthcare giant. 'Equal weight' is the investment view but the price target is 347p or 24% higher than today's 276.4p, up 2%.
- 10/11/2022
|
GSK's Key Drugs to Drive Sales in a Sluggish Second Half
- GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix are driving sales, making up for the lower sales of established drugs due to generic erosion.
- 10/05/2022
|
AstraZeneca, BAT, Ferguson, 4imprint and other exporters get double-benefit from sterling crash
- As the pound crashed following Kwasi Kwarteng's quasi-infamous ‘mini' budget, many crafty currency speculators made a quick fortune, while savvy stock market investors are still mulling which companies are likely to benefit most. Sterling has never been so weak, which in theory should make products sold by UK exporters potentially very much more attractive.
- 09/27/2022
|
Haleon impresses UBS but Barclays 'prefers to wait until Zantac visibility improves'
- Results from Haleon PLC (LSE:HLN, NYSE:HLN) and its rejection of GSK and Pfizer's request for indemnification impressed analysts UBS, who said this should allow the focus to return to the consumer healthcare group's "compelling prospects". Barclays, however, noted that GSK has contested Haleon's stance, saying “we do not agree with Haleon's position given we believe there are grounds for us to bring indemnification claims regarding certain potential liabilities (including against Haleon)” in a statement emailed out by investor relations.
- 09/21/2022
|
Haleon impresses with results and rejection of indemnity requests from GSK and Pfizer
- Haleon PLC (LSE:HLN, NYSE:HLN) shares recouped some of their losses since being spun out of GSK earlier this year as the consumer healthcare group rejected any liability in the Zantac lawsuits that have hit its parent hard. As well as publishing its maiden interim results, including a 13.4% increase in revenues £5.2bn and a 22% jump in profits, the FTSE 100-listed group said it had rejected requests from GSK and Pfizer to provision for costs related to the Zantac lawsuits in the US.
- 09/20/2022
|
Haleon share price: Inverted H&S points to a strong rebound
- Haleon (LON: HLN) share price tilted upwards on Tuesday after the company published mild financial results. The stock rose to a high of 267p, which was slightly above Friday's low of 260p.
- 09/20/2022
|
Haleon says positive momentum continuing, albeit at slower rate
- Haleon PLC (LSE:HLN, NYSE:HLN) reported a 22% increase in profits in its first set of results after being spun out of GSK, while adding that positive momentum seen in the first half has slowed very slightly in the third quarter. The FTSE 100-listed consumer healthcare group said it still maintained its guidance for full-year organic sales growth of 6-8% and that the business is “well positioned to navigate the current macro-economic challenges including rising inflation and the potential impact this may have on consumer behaviour in the future”.
- 09/20/2022
|
Haleon rejects Zantac indemnification requests from GSK, Pfizer
- Haleon on Tuesday said it had notified GSK and Pfizer that it had rejected their requests for indemnification in relation to U.S.-based litigation over the heartburn drug, Zantac.
- 09/20/2022
|
Haleon half-year results will reveal if its brands are resisting trading-down effect
- Haleon PLC (LSE:HLN, NYSE:HLN) will report its first results as a standalone business on Tuesday, after being spun out of GSK PLC (LSE:GSK, NYSE:GSK) in the summer as the largest newcomer on the London Stock Exchange for over a decade. Listed on the FTSE 100 and on the NYSE, the group, in which American giant Pfizer also has a significant stake, is one of the world's largest makers of consumer healthcare products, owning brands from Sensodyne and Aquafresh toothpaste, Voltarol and Panadol pain relief, to as respiratory, digestive health, vitamins and supplements.
- 09/16/2022
|
Haleon Resistant To Consumer Pains
- Haleon is a result of a demerger of the consumer business from GSK. It contains consumer-facing brands like Voltaren, some supplements, and various well-known toothpaste names.
- 09/05/2022
|
Haleon: Undervalued With Clear Catalyst Ahead
- Haleon has tumbled 20% since trading began in July. The stock is undervalued relative to its peers.
- 08/31/2022
|
Haleon plc: Bullish On The Market's Newest Consumer Healthcare Blue Chip
- Haleon is the spin-off of GSK plc's consumer healthcare unit. A market-leading brand portfolio supports a positive long-term outlook.
- 08/23/2022
|
Potential Lawsuits Causing Zantac Manufacturers Heartburn
- Concerns over potential liability for a medication purported to cause cancer sliced billions off the value of several manufacturers of the drug in the past week. But were the cuts too deep?
- 08/15/2022
|
Bert's July Dividend Income Summary | Dividend Investing 2022
- Our total dividend income decreased from $771.96 received in July 2021. Canadian Imperial takes the crown for the largest dividend payment of the month.
- 08/15/2022
|
PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation
- Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).
- 08/12/2022
|
Pharma companies see sales slump amid ongoing Zantac litigation
- Yahoo Finance health care reporter Anjalee Khemlani looks at which pharmaceutical stocks are being affected by litigation surrounding alleged carcinogenic materials in Zantac derivatives.
- 08/12/2022
|
Drugmaker stocks slammed over Zantac lawsuit concerns
- Thousands of lawsuits have been filed against companies including Sanofi, GlaxoSmithKline, Haleon and Pfizer accusing them of failing to properly warn users of the recalled heartburn drugs' health risks.
- 08/12/2022
|
Drugmakers' shares tumble on growing investor fears over Zantac litigation
- CNBC's Julianna Tatelbaum discusses U.S. litigation focused on heartburn drug Zantac.
- 08/12/2022
|
GSK, Sanofi and Haleon shares stabilise after Zantac litigation slump
- Shares in GSK, Sanofi
- 08/12/2022
|
GSK and Haleon given headache by cancer-linked heartburn drug
- GSK PLC (LSE:GSK, NYSE:GSK) and Haleon PLC (LSE:HLN, NYSE:HLN) were the biggest FTSE 100 fallers on Thursday amid investor concerns surrounding US lawsuits over heartburn drug, which was withdrawn from the market in 2019 on cancer fears. Shares in pharma giant GSK, which specialises in infectious diseases, HIV, oncology and immunology, sunk 8.8% to 1,419p, while its recent consumer healthcare spinoff declined 7.7% to 258p on the news.
- 08/11/2022
|
Pharma Stocks GSK, Sanofi And Haleon Lose Billions As Zantac Trial Looms
- Pharmaceutical stocks GSK, Sanofi and Haleon extended deep losses Thursday amid looming litigation around recalled heartburn drug Zantac. The post Pharma Stocks GSK, Sanofi And Haleon Lose Billions As Zantac Trial Looms appeared first on Investor's Business Daily.
- 08/11/2022
|
Drug stocks under pressure over Zantac litigation concerns
- Dr. Scott Gottlieb, former FDA commissioner and CNBC contributor, joins CNBC's 'Squawk Box' to discuss alleged concerns that Sanofi and GSK's antacid drug Zantac causes cancer.
- 08/11/2022
|
Haleon not a party to U.S. litigation focused on Zantac - spokesperson
- Haleon - GSK's recently spun off consumer health unit - is not a party to the U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday.
- 08/11/2022
|
GSK, Sanofi and Haleon slump on worries over Zantac litigation
- European-listed shares of drugmakers Haleon HLN, -11.81% , GSK GSK, -8.48% and Sanofi SAN, -8.81% plunged on Thursday on worries over the Zantac heartburn medication litigation. The first trial is set to begin on Aug. 22.
- 08/11/2022
|
Haleon: The 'Good Health Lion' Now Stalks the Drug Store Aisle
- Haleon PLC ( HLN , Financial) is the world's largest consumer health care company, which was recently spun off of GSK PLC ( GSK , Financial). The company's name was formed from merging the words "hale," which means in good health, and "leon," which is associated with the word Spanish word for lion.
- 08/04/2022
|
Is Haleon a buy? This leading US broker delivers its verdict
- Panadol maker Haleon PLC (LSE:HLN, NYSE:HLN) delivered a ‘solid first building block' with an upbeat trading statement a little over a week after its £30bn spin-out from GSK PLC (LSE:GSK, NYSE:GSK). That at least was the conclusion of US bank Jefferies, which specialises in analysing health and drug stocks.
- 07/29/2022
|
GSK or Haleon: Which Is the Real Beneficiary of This Spinoff?
- GSK PLC ( GSK , Financial) completed the long-awaited spinoff of its consumer health care business Haleon ( HLN , Financial) on July 18. Shareholders received one Haleon share for each GSK share owned.
- 07/27/2022
|
Unilever, Reckit and Haleon stand strong in tough times, but can it last?
- Consumer goods companies enjoyed a strong week, but what makes them so special? Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB), Unilever PLC (LSE:ULVR) and Haleon PLC (LSE:HLN, NYSE:HLN) are the consumer goods FTSE 100 companies which all posted an impressive set of results and raised guidance for the year.
- 07/27/2022
|
